Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP002012)
SBP Name
DARPin Abicipar pegol
Synonyms
AGN-150998; MP0112; abicipar; Allergan plcMolecular Partners
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Preregistration
Protein Scaffold Information of This SBP
Scaffold ID PS027
Scaffold Info
[1] , [2] , [3]
Scaffold Name DARPin
Scaffold Class Non-Antibody
Fold Type Alpha-Helices + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Vascular endothelial growth factor A
BTS Info
Inhibitor Age related macular degeneration [ICD-11: 9B75.0Z]; Diabetic macular oedema [ICD-11: 9B71.02] Kd: 0.002 nM Molecular Partners; Texas Retina Associates; Allergan [1] , [2] , [3]
Clinical Trial Information of This SBP
EUCTR2014-004579-22-AT Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-CEDAR
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004579-22-CZ Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-CEDAR
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004579-22-DE Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-CEDAR
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004579-22-ES Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-CEDAR
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004579-22-LV Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-CEDAR
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004580-20-DK Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-SEQUOIA
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004580-20-HU Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-SEQUOIA
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004580-20-IT Click to show the Detail
Indication Age-related macular degeneration
Phase .
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-SEQUOIA
Status Authorised
Sponsor Allergan
EUCTR2014-004580-20-NL Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-SEQUOIA
Status Not Recruiting
Sponsor Allergan
EUCTR2014-004580-20-PL Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration-SEQUOIA
Status Not Recruiting
Sponsor Allergan
NCT02181504 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase II
Title A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
Status Completed
Sponsor Allergan
NCT02181517 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase II
Title A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Status Completed
Sponsor Allergan
NCT02186119 Click to show the Detail
Indication Diabetic Macular Edema (DME)
Phase Phase II
Title A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
Status Completed
Sponsor Allergan
NCT02462486 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Status Completed
Sponsor Allergan
NCT02462928 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Status Completed
Sponsor Allergan
NCT02859766 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase I
Title Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
Status Completed
Sponsor Allergan
NCT03335852 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase I
Title Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD
Status Completed
Sponsor Allergan
NCT03539549 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase II
Title A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)
Status Completed
Sponsor Allergan
PER-065-15 Click to show the Detail
Indication Age-related macular degeneration
Phase Phase III
Title Safety And Efficacy Of Abicipar Pegol (AGN-150998) In Patients With Neovascular Age-Related Macular Degeneration
Status Recruiting
Sponsor Allergan
References
1 Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration. J Ocul Pharmacol Ther. 2018 Dec;34(10):700-709.
2 In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018 Jan;9(1):3-14.
3 A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition. J Pharmacol Exp Ther. 2020 May;373(2):184-192.